Navigation Links
Infinity and MedImmune Announce Updated Data On Ipi-504 to be,Presented At ASCO

CAMBRIDGE, Mass. and GAITHERSBURG, Md., May 31, 2007 (PRIME NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) and MedImmune, Inc. (Nasdaq:MEDI) today announced that interim clinical data on IPI-504 in a Phase I trial in patients with gastrointestinal stromal tumors (GIST) and other soft tissue sarcomas (STS), will be presented at the 2007 Annual Meeting of the American Society of Clinical Oncology (ASCO), to be held June 1-5, 2007 at McCormick Place in Chicago, Ill. IPI-504, the companies' heat shock protein 90 (Hsp90) inhibitor, is currently being evaluated as a water-soluble, intravenous formulation in two disease-focused clinical trials involving patients with GIST/STS and non-small cell lung cancer (NSCLC).

* A poster entitled, "Inhibition and flare patterns of metabolic response to the heat shock protein 90 (Hsp90) inhibitor IPI-504 visualized by FDG-PET in patients (pts) with advanced gastrointestinal stromal tumors (GIST) resistant to tyrosine kinase inhibitor (TKI) therapy," (Poster Number 1, Abstract No: 3530) will be presented on Saturday, June 2, 2007 from 2:00-6:00 p.m. CDT in Room S102a.

* A poster entitled, "Inhibition of the Heat Shock Protein 90 (Hsp90) chaperone with the novel agent IPI-504 to overcome resistance to tyrosine kinase inhibitors (TKIs) in metastatic GIST: Updated results of a phase I trial," (Poster Number 8, Abstract No: 10023) will be presented on Monday, June 4, 2007 from 2:00-6:00 p.m. CDT in Room S103a.

About IPI-504

IPI-504 is a small molecule drug candidate being developed jointly by Infinity and MedImmune. IPI-504 has been well tolerated in its ongoing Phase I studies and has shown promising biological activity in a Phase I clinical trial in patients with relapsed, refractory, Gleevec(r)-resistant GIST. IPI-504 is also being evaluated in a Phase I/II clinical trial in patients with advanced NSCLC. In preclinical studies, IPI-504 has been
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Infinity and MedImmune Present Updated Phase I Results of IPI-504 in GIST at ASCO Annual Meeting
2. Infinity and MedImmune to Present Preclinical Data From Study of Oral Formulation of IPI-504 At AACR
3. MedImmune Highlights Advances in Inflammatory Disease Pipeline With Series of Data Presentations
4. MedImmune Announces Positive Clinical Results at PAS Annual Meeting From Large Prospective Trial in Prevention of Serious RSV Disease
5. Pediatric Academic Societies Annual Meeting to Feature Data Presentations Related to MedImmune Clinical Programs in Influenza, RSV and hMPV
6. Micromet Achieves Milestone in BiTE Research Collaboration with MedImmune
7. MedImmune Publishes New Data in Nature Immunology Demonstrating The Role HMGB1 May Play in Systemic Autoimmune Diseases
8. MedImmune and Micromet Publish Data on Novel Anti-Cancer BiTE Molecule
9. Micromet and MedImmune Present Data From Preclinical Study of New BiTE Molecule Targeting CEA
10. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
11. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Infinity and MedImmune Announce Updated Data Ipi Presented ASCO
(Date:7/25/2014)... , July 25, 2014 /PRNewswire-iReach/ -- "Australia Capsule ... data on the Australia Capsule Endoscopy Systems market. The ... (in units) and average prices (in US dollars) within ... , Capsule Endoscopes , Capsule ... The report also provides company shares and ...
(Date:7/25/2014)... MISSION, Kan. , July 25, 2014 /PRNewswire-iReach/ ... , and TCGRx, of Powers Lake, ... exclusive partners in a distribution and co-marketing agreement ... to retail pharmacies throughout the United ... of robotics-based pharmacy management and workflow systems to ...
(Date:7/25/2014)... , July 25, 2014 GrowBLOX Sciences, Inc. (OTCQB: ... Memorandum of Understanding ("MOU") with LaurelCo, LLC, an ... acquisition of both cultivation and dispensary medical marijuana licenses in ... the MOU, GBLX will acquire a 20% equity interest in ... GrowBLOX TM growing chambers, as well as all technology ...
Breaking Medicine Technology:Australia Capsule Endoscopy Systems Market Analysis and Forecast to 2020 2Australia Capsule Endoscopy Systems Market Analysis and Forecast to 2020 3Australia Capsule Endoscopy Systems Market Analysis and Forecast to 2020 4Australia Capsule Endoscopy Systems Market Analysis and Forecast to 2020 5ScriptPro and TCGRx Integrate Pharmacy Automation Technologies 2ScriptPro and TCGRx Integrate Pharmacy Automation Technologies 3GrowBLOX Sciences, Inc. Partners with LaurelCo, LLC to Obtain Licenses to Cultivate and Dispense Medical Marijuana in Illinois 2GrowBLOX Sciences, Inc. Partners with LaurelCo, LLC to Obtain Licenses to Cultivate and Dispense Medical Marijuana in Illinois 3
... ACCESS PHARMACEUTICALS, INC.,(OTC Bulletin Board: ACCP) announced ... performed by Access collaborators at two,prominent institutes ... the joint,symposium of the American Association for ... European Organization for Research and Treatment,of Cancer ...
... Cells has Potential to Yield High ... and Therapeutic Products, ST. LOUIS and RICHMOND, Calif., Oct. ... Inc.,(Nasdaq: SGMO ) announced today the publication of data ... human stem,cells. This work represents a significant advance in the ...
Cached Medicine Technology:Access Pharmaceuticals Announces Two Poster Presentations Reporting Significant Preclinical Data on ProLindac(TM) at the AACR-NCI-EORTC 'Molecular Targets and Cancer Therapeutics' Conference 2Access Pharmaceuticals Announces Two Poster Presentations Reporting Significant Preclinical Data on ProLindac(TM) at the AACR-NCI-EORTC 'Molecular Targets and Cancer Therapeutics' Conference 3Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells 2Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells 3Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells 4Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells 5
(Date:7/26/2014)... 26, 2014 The number of Stryker ... federal litigations since the 2012 recall of Rejuvenate and ... Bernstein Liebhard LLP reports. According to a case list ... have been filed in the New Jersey’s Bergen County ... the ABG II Modular Hip Stem Litigation, No. 296) ...
(Date:7/26/2014)... 2014 As reported by Lauren ... based on 3 factors: smaller spaces, multi-generational access, and ... trend of 2014 lists, including this article on ... Amerec , a leading manufacturer of steam bath generators, ... due to smaller spaces and an effort to reduce ...
(Date:7/26/2014)... (PRWEB) July 26, 2014 ... recently updated by Vkool.com, this is a ... safe methods for treating all types of ...     Tinnitus due to Ménière's ... ,     Nerve pathway tinnitus , ...
(Date:7/26/2014)... 2014 Multiple sclerosis (MS), also ... an inflammatory disease in which the insulating covers ... cord are damaged. This damage disrupts the ability ... resulting in a wide range of signs and ... Multiple sclerosis takes several forms, with new symptoms ...
(Date:7/26/2014)... (PRWEB) July 26, 2014 Another DePuy Pinnacle ... Orthopedics, Inc., has been filed by Wright & Schulte LLC. ... on behalf of an Erie County, Ohio man who ... left hip and groin since receiving his Pinnacle Hip implant ... man will be forced to undergo a complex and risky ...
Breaking Medicine News(10 mins):Health News:Stryker Hip Lawsuit Filings in State and Federal Litigations Continue to Rise, Bernstein Liebhard LLP Reports 2Health News:Stryker Hip Lawsuit Filings in State and Federal Litigations Continue to Rise, Bernstein Liebhard LLP Reports 3Health News:Amerec Finds Bathroom Design Trends Change Based on Water Consumption and Other Factors 2Health News:Tinnitus Miracle Book Review Exposes Thomas Coleman's Guide for Treating Tinnitus – Vkool.com 2Health News:Multiple Sclerosis Therapeutics Clinical Trials Market Review H2 2014 Analysis Report Available at MarketOptimizer.org 2Health News:Multiple Sclerosis Therapeutics Clinical Trials Market Review H2 2014 Analysis Report Available at MarketOptimizer.org 3Health News:Multiple Sclerosis Therapeutics Clinical Trials Market Review H2 2014 Analysis Report Available at MarketOptimizer.org 4Health News:DePuy Pinnacle Hip Lawsuit Filed By Wright & Schulte LLC On Behalf of Recipient Who Faces Surgery To Replace Artificial Hip Implant 2Health News:DePuy Pinnacle Hip Lawsuit Filed By Wright & Schulte LLC On Behalf of Recipient Who Faces Surgery To Replace Artificial Hip Implant 3Health News:DePuy Pinnacle Hip Lawsuit Filed By Wright & Schulte LLC On Behalf of Recipient Who Faces Surgery To Replace Artificial Hip Implant 4Health News:DePuy Pinnacle Hip Lawsuit Filed By Wright & Schulte LLC On Behalf of Recipient Who Faces Surgery To Replace Artificial Hip Implant 5
... Nearly half of women treated for breast cancer did ... years are roughly the same whether they undergo mastectomy or ... be aware of this important factor of their treatment decision, ... Cancer Center. , Minority women were also less likely to ...
... new products introduced at the AHRMM08 Annual Conference & Exhibition, ... for purchase on limited release. , ... ... the company who pioneered web-based http://www.vendorclear.com/ [vendor ...
... July 30 Wounded Warrior Project,(WWP), a ... warriors,today announced that Michael Ward, chairman and ... wife Terry have personally contributed $1 million,toward ... donation is to support WWP,s new initiative ...
... strong, 85.6 million U.S., adults have doubted their opinion or ... information ... Hispanics most likely to rely on friends and family, NEW ... say they have doubted a medical professional,s,opinion or diagnosis because it conflicted ...
... (NYSE: ACS ) today announced a $4 million ... of New Orleans Emergency,Medical Services (EMS) agency., Under ... all New,Orleans, ambulances with the state-of-the-art FIREHOUSE (FH) Mobile ... patient data in,real-time, whether in the field at a ...
... 30 In conjunction,with DURECT Corporation,s (Nasdaq: ... you are invited to listen to the conference ... on Wednesday, August 6, 2008,at 9:00 a.m. EDT ... A live audio webcast of the presentation ...
Cached Medicine News:Health News:Minorities less likely to know about breast cancer treatment options 2Health News:Minorities less likely to know about breast cancer treatment options 3Health News:VendorClear™ Announces Limited Release of New Products for Healthcare Facilities and Vendor Representatives 2Health News:Michael and Terry Ward Donate $1 Million to Wounded Warrior Project (WWP) 2Health News:Dr. Web Makes Many Americans Question Trusted Health Providers 2Health News:Dr. Web Makes Many Americans Question Trusted Health Providers 3Health News:ACS Awarded $4 Million Contract to Provide Electronic Patient Records for City of New Orleans EMS 2Health News:DURECT Corporation Invites You to Join Its Second Quarter 2008 Earnings Conference Call 2
... three conventional measurement modes (Phakic, Aphakic, and ... new axial length measuring mode. Normal phakic ... velocity for conversion at 1550m/s. The new ... each tissues sonic velocity for conversion: anterior ...
... very high frequency digital ultrasound eye arc-scanner. ... microscopic resolution images and precision measurement capabilities ... the human eye. Artemis is a very ... use, the patient leans forward placing their ...
... the most advanced ophthalmic ultrasound available today. ... a single Macintosh desktop or laptop computer ... internal probe rotator. Every aspect of the ... 12 MHz B-probe operates on an entirely ...
... The AB5500 is a combination A-scan and ... capabilities. The A-scan incorporates a high frequency, ... which enables scan capture immediately upon application ... In cases where the axial length of ...
Medicine Products: